

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222(ChAdOx1.nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
AZD1222 US Phase 3
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> Lawrence Corey <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences	Grant / Contract	Self
<i>Recipient Name:</i> Lundquist Institute at Harbor-UCLA Medical Center <i>Grant / Contract Description:</i> Research of HIV-related products <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Gilead Sciences	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Part of independent panel of grant reviewers for a Gilead funding program.		<i>Description:</i> Consultant on HIV related products
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Ad hoc consultant for HIV products		<i>Description:</i>
ViiV Healthcare	Grant / Contract	Self
<i>Recipient Name:</i> Lundquist Institute at Harbor-UCLA Medical Center <i>Grant / Contract Description:</i> HIV related studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
ViiV Healthcare	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Ad hoc consultant		<i>Description:</i> Consultant for HIV-related products

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Self
<i>Recipient Name:</i> Orlando Immunology Center <i>Grant / Contract Description:</i> Conduction of COVID research studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Boehringer Ingelheim	Grant / Contract	Self
<i>Recipient Name:</i> Orlando Immunology Center <i>Grant / Contract Description:</i> Conduction of COVID research studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
F. Hoffmann-La Roche	Grant / Contract	Self
<i>Recipient Name:</i> Orlando Immunology Center <i>Grant / Contract Description:</i> Conduction of COVID research studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Gilead Sciences	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Twice yearly meetings		<i>Description:</i> HIV National Advisory Board
Gilead Sciences Inc	Grant / Contract	Self
<i>Recipient Name:</i> Orlando Immunology Center <i>Grant / Contract Description:</i> Conduction of HIV and HCV clinical research studies and research grants <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
GlaxoSmithKline, LLC.	Grant / Contract	Self
<i>Recipient Name:</i> Orlando Immunology Center <i>Grant / Contract Description:</i> Conduction of HIV and COVID research studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Johnson & Johnson Health Care Systems Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Orlando Immunology Center <i>Grant / Contract Description:</i> Conduction of COVID research studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
National Institute of Allergy and Infectious Diseases	Grant / Contract	Self
<i>Recipient Name:</i> Orlando Immunology Center <i>Grant / Contract Description:</i> Conduction of HIV and COVID Clinical Research Trials <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Regeneron Pharmaceuticals	Grant / Contract	Self
<i>Recipient Name:</i> Orlando Immunology Center <i>Grant / Contract Description:</i> Conduction of COVID research studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19Vaccine
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Anna Durbin

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Fred Hutchinson Cancer Research Center	Grant / Contract	Other - AstraZeneca
<i>Recipient Name:</i> Johns Hopkins University <i>Grant / Contract Description:</i> Conduct of the Phase 3 clinical trial of the safety and efficacy of ChAdOx1 Covid vaccine		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i> I was the site PI for this trial
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> I consult with Merck for approximately 24 hours a year		<i>Description:</i> I provided expertise for Merck's dengue vaccine development program
Pfizer	Grant / Contract	Other - Pfizer
<i>Recipient Name:</i> Johns Hopkins University <i>Grant / Contract Description:</i> Phase 3 evaluation of the safety and efficacy of the BNT162b2 COVID vaccine		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i> Investigator
Valneva Austria GmbH	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> I provide expertise for their vaccine development program. This includes a vaccine for COVID.		<i>Description:</i> I am on the scientific advisory board for Valneva

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

 - Please describe those relationships.**

The National Institutes of Health provided funding to my institution for the conduct of the trial.
- What is the manuscript title?**

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
BioFire Diagnostics, LLC	Grant / Contract	Self
<i>Recipient Name:</i> University of Rochester <i>Grant / Contract Description:</i> Improved diagnostics for respiratory infection <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Janssen Biotech	Grant / Contract	Self
<i>Recipient Name:</i> University of Rochester <i>Grant / Contract Description:</i> Vaccine and Epidemiology <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Merck	Grant / Contract	Self
<i>Recipient Name:</i> University of Rochester <i>Grant / Contract Description:</i> Epidemiology of RSV <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Novavax	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i> COVID Vaccine DSMB
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> University of Rochester <i>Grant / Contract Description:</i> Vaccine Trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Global Clinical Head <i>Additional Information:</i>		<i>Position Description:</i> Clinical Development
AstraZeneca	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Global Clinical Head <i>Additional Information:</i>		<i>Position Description:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Other	Other - Hassman Research Institute
<i>Category: Other</i> <i>Additional Information: Clinical Trial Investigator</i>		<i>Description: Clinical Trial</i>
janssen vaccines and prevention B.V.	Other	Other - Hassman Research Institute
<i>Category: Other</i> <i>Additional Information: Clinical Trial Investigator</i>		<i>Description: Clinical Trial</i>
Medicago	Other	Other - Hassman Research Institute
<i>Category: Other</i> <i>Additional Information: Clinical Trial Investigator</i>		<i>Description: Clinical Trial</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Executive Director, Statistics <i>Additional Information:</i>		<i>Position Description:</i> Biometrics Strategy Lead
AstraZeneca	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Director, Clinical Virology <i>Additional Information:</i> Full time employee		<i>Position Description:</i> Head of clinical virology
AstraZeneca	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Self

Recipient Name: UC Regents
Grant / Contract Description: Phase 3 RCT of AZD1222 vs. placebo for prevention of COVID-19
Additional Information:

Recipient Type: Institution
Grant / Contract Purpose: Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Senior Global Development Medical Director <i>Additional Information:</i>		<i>Position Description:</i>
AstraZeneca	Employment	Spouse/Partner
<i>Title:</i> Senior Global Development Medical Director <i>Additional Information:</i>		<i>Position Description:</i>
AstraZeneca	Stock	Self
<i>Additional Information:</i>		
AstraZeneca	Stock	Spouse/Partner
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Senior Vice President, R&D		<i>Position Description:</i> Head of late phase drug development for Respiratory, Immunology and Infection
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Other	Other - HealthPartners Institute
<i>Category:</i> Other <i>Additional Information:</i> Site PI for AZD1222 vaccine trial.		<i>Description:</i> Research Grant support to HealthPartners Institute for current trial

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Senior Director Scientist <i>Additional Information:</i>		<i>Position Description:</i> Clinical Scientist
AstraZeneca	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Eli Lilly and Company	Grant / Contract	Self
<i>Recipient Name:</i> Mark J. Mulligan MD FIDSA <i>Grant / Contract Description:</i> clinical research; laboratory research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
meissa vaccines	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> relating to covid vaccine development		<i>Description:</i> scientific advisory board
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Mark Mulligan <i>Grant / Contract Description:</i> Pfizer Covid vaccines clinical trials <i>Additional Information:</i> research contract to NYU; i also serve on the Pfizer covid advisory board		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
SANOFI PASTEUR INC.	Grant / Contract	Self
<i>Recipient Name:</i> Mark J. Mulligan MD FIDSA <i>Grant / Contract Description:</i> vaccine trials <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Kathleen Neuzil <i>Grant / Contract Description:</i> Phase I Clinical trial of mRNA vaccine candidate <i>Additional Information:</i> Dr. Neuzil received no salary support. Her institution received support for conduct of this trial.		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Gilead Sciences Inc	Other	Self
<i>Category:</i> Other <i>Additional Information:</i> PI for LEN PrEP study		<i>Description:</i> Principal Investigator for clinical trial
ViiV Healthcare	Other	Self
<i>Category:</i> Other <i>Additional Information:</i> Served on Advisory Board for 1 day in the past year. Have served on ViiV advisory boards in previous years as well		<i>Description:</i> Served on Advisory Board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Merck	Consultant	Self
Category: Consultant Additional Information: Presented and participated at forum		Description: service on US Vaccine Confidence Expert Input Forum
Pfizer	Consultant	Self
Category: Consultant Additional Information: Limited time Consultant for topic specific broadcast		Description: Consultant for Spring 2021 Trumenba Premiere Broadcast
Pfizer	Consultant	Self
Category: Consultant Additional Information: Time limited consultant for topic specific activity		Description: Consultant for Pediatric Pneumococcal PEGASUS
Pfizer	Consultant	Self
Category: Consultant Additional Information: limited time consultant for topic specific story		Description: Consultant for Trumenba Science Story
Pfizer	Consultant	Self
Category: Consultant Additional Information: Consultant for one time meeting on topic specific discussion		Description: Consultant for Virtual Discussion about future pediatric PCV recommendations in the US
SANOFI PASTEUR INC.	Consultant	Self
Category: Consultant Additional Information: limited time scientific/vaccine consultant for the production of educational videos to support HCPs in managing vaccine hesitancy		Description: Scientific consultant & Medical Expert
SANOFI PASTEUR INC.	Consultant	Self
Category: Consultant Additional Information: Served as speaker to healthcare professionals on topics specific to vaccines & vaccine hesitancy		Description: provided presentations as requested
SANOFI PASTEUR INC.	Consultant	Self
Category: Consultant Additional Information: Hotel and flight was booked by the funder		Description: Presented at the International Forum Voices for Vaccination on 8/29/19 in Mexico City, MX

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Executive Vice President <i>Additional Information:</i>		<i>Position Description:</i> Global Head of BioPharmaceutical R&D
AstraZeneca	Stock	Self
<i>Additional Information:</i>		
GlaxoSmithKline	Stock	Self
<i>Additional Information:</i>		
Johnson and Johnson	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
phase3 safety and efficacy of AZD 1222
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Statistical Science Director <i>Additional Information:</i>		<i>Position Description:</i>
AstraZeneca	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bill and Melinda Gates Foundation	Grant / Contract	Other - Research grant
<i>Recipient Name:</i> Columbia University <i>Grant / Contract Description:</i> Grant to conduct HIV research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Gilead Sciences	Grant / Contract	Other - Research grant
<i>Recipient Name:</i> Columbia University <i>Grant / Contract Description:</i> Grant to conduct HIV prevention research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Janssen Global Services, LLC	Grant / Contract	Other - Research grant
<i>Recipient Name:</i> Columbia University <i>Grant / Contract Description:</i> Grant to conduct HIV vaccine study <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Merck	Grant / Contract	Other - Research grant
<i>Recipient Name:</i> Columbia University <i>Grant / Contract Description:</i> Grant to conduct HIV prevention reserach <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
SANOFI PASTEUR INC.	Grant / Contract	Other - Research grant
<i>Recipient Name:</i> Columbia University <i>Grant / Contract Description:</i> Grant to conduct COVID vaccine research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Statistical consultant
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Statistical consultant for AstraZeneca

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Senior Global Clinical Operations Program Lead <i>Additional Information:</i>		<i>Position Description:</i>
AstraZeneca	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-05290

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Employment	Self
<i>Title:</i> Vice President, Global Franchise Head Infection <i>Additional Information:</i>		<i>Position Description:</i> Responsible for R&D for infectious disease assets

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV- 19) COVID-19 Vaccine

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Ann Falsey, Magdalena Sobieszczyk, Ian Hirsch, Stephanie Sproule, Merlin Robb, Larry Corey, Kathy Neuzil, William Hahn, Julie Hunt, Mark Mulligan, Charlene McEvoy, Edwin DeJesus, Micheal Hassman, Susan Little, Barbara Pahud, Anna Durbin, Paul Pickrell, Eric Daar, Larry Bush, Joel Solis, Quito Osuna Carr, Temitope Oyadele, Susan Buchbinder, Jessica Cowden, Sergio Vargas, Alfredo Guerrerros Benavides, Robert Call, Michael Keefer, Beth Kirkpatrick, John Pullman, Tina Tong, Margaret Brewinski Isaacs, David Benkeser, Holly Janes, Martha Nason, Justin Green, Elizabeth Kelly, Jill Maaske, Nancy Mueller, Kathryn Shoemaker, Therese Takas, Richard Marshall, Menelas N Pangalos, Tonya Villafana, Antonio Gonzalez Lopez.

Certification

I certify that the information provided in this disclosure is complete and accurate.